The epicardium plays an essential role in coronary artery formation and myocardial development, but signals controlling the development and differentiation of this tissue are not well understood. To investigate the role of platelet-derived growth factor receptor (PDGFR)␤ in development of epicardial-derived vascular smooth muscle cells (VSMCs), we examined PDGFR␤ Ϫ/Ϫ and PDGFR␤ epicardial mutant hearts. We found that PDGFR␤ Ϫ/Ϫ hearts failed to form dominant coronary vessels on the ventral heart surface, had a thinned myocardium, and completely lacked coronary VSMCs (cVSMCs). This constellation of defects was consistent with a primary defect in the epicardium. To verify that these defects were specific to epicardial derivatives, we generated mice with an epicardial deletion of PDGFR␤ that resulted in reduced cVSMCs distal to the aorta. The regional absence of cVSMCs suggested that cVSMCs could arise from 2 sources, epicardial and nonepicardial, and that both were dependent on PDGFR␤. In the absence of PDGFR␤ signaling, epicardial cells adopted an irregular actin cytoskeleton, leading to aberrant migration of epicardial cells into the myocardium in vivo. In addition, PDGF receptor stimulation promoted epicardial cell migration, and PDGFR␤-driven phosphoinositide 3Ј-kinase signaling was critical for this process. Our data demonstrate that PDGFR␤ is required for the formation of 2 distinct cVSMC populations and that loss of PDGFR␤-PI3K signaling disrupts epicardial cell migration.
V ascular smooth muscle cells (VSMCs) arise from a diverse range of tissues including neural crest, somites, splanchnic mesoderm, gut mesothelium, and epicardium (reviewed by Majesky 1 ) , and past data have demonstrated that many coronary VSMCs (cVSMCs) are derived from the embryonic epicardium. 2, 3 Whereas several genes have been identified that are essential for the formation, attachment, and spreading of the epicardium, few genes have been identified that are essential during epithelial-to-mesenchymal transition (EMT) and subsequent differentiation into cVSMCs and cardiac fibroblasts.
Platelet-derived growth factor receptor (PDGFR) tyrosine kinases are 1 family of signaling proteins that are potentially involved in epicardial cell function. Analyses in the mouse have shown that PDGFR␤ signaling promotes proliferation and migration of VSMCs in multiple vascular beds including the heart. 4 -8 Therefore, we investigated the function of PDGFR␤ signaling during epicardial development. We have examined PDGFR␤ Ϫ/Ϫ , epicardial-specific PDGFR␤ mu-tant, and PDGFR␤ signaling-deficient embryos. We discovered that epicardial deletion resulted in the absence of cVSMCs distal to the aorta and that PDGFR␤ signaling through phosphoinositide 3Ј-kinase (PI3K) was required for proper cytoskeletal organization in epicardial cells. Our results designate PDGF receptor signaling as another growth factor system involved in epicardial development.
Materials and Methods

Experimental Animals
Mice were maintained on a mixed C57Bl/6ϫ129SV background. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Southwestern Medical Center and performed according to the Guide for the Care and Use of Laboratory Animals, published by the NIH. Dr Eric Olson kindly provided capsulin LacZ/ϩ mice, 17 and Dr Pilar Ruiz-Lozano kindly provided Gata5Cre Tg/0 mice. 9 The expanded Materials and Methods section in the online data supplement, available at http://circres.ahajournals.org, provides additional strain and breeding information.
Migration
Embryonic day (E)12.5 hearts were isolated from indicated genotypes and incubated with green fluorescent protein (GFP)-expressing adenovirus. Hearts were cultured in 10% FBS 1:1 DMEM:medium 199 supplemented with basic fibroblast growth factor (2 ng/mL, Sigma) for 48 hours with vehicle, 50 ng/mL PDGFBB, 50 ng/mL PDGFBBϩLY294002 (2 mol/L, Cell Signaling), hTGF␤1 (20 ng/mL, R&D Systems), or basic fibroblast factor (25 ng/mL, Sigma). Hearts were isolated, fixed, and frozen-embedded as performed in the carboxyfluorescein (CCFSE) experiments. Ten-micron sections were DAPI-stained and mounted in 1:1 PBS glycerol. Migration was quantified by counting the number of GFP-positive cells beneath the epicardium in a ϫ40 field of view from 5 nonconsecutive sections. Percentage of migrated cells was determined by dividing the average number of GFP-positive cells for each sample by the average of wild-type GFP-positive cells that had migrated in response to PDGFBB stimulation and multiplying by 100.
Standard protocols were used for histology, immunohistochemistry, Western blotting, and primary epicardial cultures. Detailed procedures can be found in the expanded Materials and Methods section in the online data supplement.
Results
Loss of PDGFR␤ Results in Coronary Blood Vessel and Myocardial Defects
Although PDGFR␤ signaling is considered mitogenic for VSMCs, only select populations of VSMCs are affected by the loss of PDGFR␤ or PDGFB. 4 Because cVSMCs arise from a unique mesothelial origin, we wanted to determine how PDGFR␤ signaling regulates this cell population. The Gata5CreTg mouse line expresses Cre recombinase in the proepicardial organ (the embryonic source of epicardial cells) and the epicardium. 9 Crossing this transgenic line to mice with a PDGFR␤ loxP-flanked allele generated animals lacking PDGFR␤ in the epicardium (PDGFR␤ EKO ). Using mice that possessed either a PDGFR␤-null allele or this epicardial deletion of PDGFR␤, we examined coronary vessel formation.
We began our analysis by investigating the myocardial thickness in these PDGFR␤-deficient hearts. In comparison to the myocardial defects reported in PDGFR␤ Ϫ/Ϫ hearts (elsewhere 10 and data not shown), the myocardial compact zone in PDGFR␤ EKO hearts was relatively normal. PDGFR␤ EKO compact zones at E18.5 were 88Ϯ4% the thickness of controls (nϭ4 controls and nϭ4, PDGFR␤ EKO ). Therefore, the myocardial defects observed in PDGFR␤ Ϫ/Ϫ hearts may be secondary to systemic vascular defects rather than epicardial loss of PDGFR␤ because the epicardial mutant hearts had minimal myocardial disruption.
We next examined coronary artery development in these hearts. At E14.5, hearts of all genotypes possessed a capillary plexus, but PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO hearts possessed abnormal clusters of endothelial cells ( Figure 1A ). In PDGFR␤ Ϫ/Ϫ hearts, these defects persisted and dominant coronary vessels failed to form on the ventral surface. In contrast, at E17.5 endothelial vessel formation in PDGFR␤ EKO hearts was similar to wild type ( Figure 1B) . These results indicated that coronary vessel disruption occurs in PDGFR␤-deficient hearts, but, in the case of the epicardial deletion, vessel remodeling is later recovered.
To determine whether the endothelial defects were accompanied by similar VSMC defects, we generated PDGFR␤deficient animals that possessed the XlacZ4 transgene.
XlacZ4 mice express a nuclear-localized ␤-galactosidase protein in VSMCs, 11 including those derived from the epicardium (C.L.S. and M.D.T., unpublished observation, 2007). In wild-type hearts, a few ␤-galactosidase ϩ cells were observed as early as E14.5. A majority of cells were present in close proximity to nascent coronary vessels, whereas single cells were found scattered on the heart surface ( Figure 2A ). In comparison, PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO hearts contained no ␤-galactosidase ϩ cells (Figure 2A ). At E17.5, VSMCs were present in wild-type hearts both along the major coronary arteries as well as scattered along smaller vessels within the ventricles. Remarkably, E17.5 PDGFR␤ Ϫ/Ϫ hearts did not possess ␤-galactosidase ϩ cells along the heart surface or within the ventricles ( Figure 2B and data not shown), although a few ␤-galactosidase ϩ cells were observed in the aortic arch. In contrast, epicardial loss of PDGFR␤ caused loss of a majority of cVSMCs, but ␤-galactosidase ϩ cells were still present along the vessels descending from the aortic root ( Figure 2B ). The absence of cVSMCs in PDGFR␤ Ϫ/Ϫ hearts and reduction in PDGFR␤ EKO hearts was confirmed by staining for smooth muscle myosin heavy chain and ␣ smooth muscle actin (data not shown). Therefore, the requirement for PDGFR␤ in the formation of cVSMCs is different than the requirement for VSMCs in other tissues that have been investigated. The complete loss of this VSMC population in the PDGFR␤ Ϫ/Ϫ heart demonstrates a greater dependence on PDGFR␤ signaling in cVSMC development and suggests that PDGFR␤ may function beyond the role of a mitogen or chemotactic factor.
Expression of PDGF Receptors During Heart Development
To identify when PDGFR␤ was expressed in the heart, we examined wild-type embryos at various stages of coronary vascular development. Consistent with chick expression studies, 12 PDGFR␤ was expressed as early as E9.5 in the proepicardium (data not shown). At E13.5, we observed PDGFR␤ in the cells of the epicardium. At E15.5 PDGFR␤ expression remained in the epicardium but was also observed in cells surrounding vessels within the myocardium. By E17.5, PDGFR␤ expression was reduced in the epicardium, and the majority of positive cells were presumably VSMCs adjacent to endothelial vessels ( Figure II , A, in the online data supplement).
Recent reports have also demonstrated that PDGFR␣ is expressed by epicardial cells. 13 Using an allele of the PDGFR␣ that expresses a nuclear localized green fluorescent protein from the PDGFR␣ locus, 14 we investigated the spatial and temporal expression of this receptor. Similar to PDGFR␤, PDGFR␣ is expressed by epicardial cells (supplemental Figure II 
Nonepicardial Source for cVSMCs
We next investigated the source of the persisting cVSMCs present in PDGFR␤ EKO hearts. From the whole-mount images, we found that cVSMCs were present at the aortic root. We then quantified the number of cVSMCs and found that PDGFR␤ EKO hearts contained similar numbers of cVSMCs in the base of the heart but exhibited a significant reduction of these cells within the heart apex (supplemental Figure III) .
This region-specific loss of cVSMCs suggested that these cVSMCs arise from an origin separate from the epicardium or that recombination of the PDGFR␤ locus was inefficient or too late. To test these possibilities, we examined PDGFR␤ expression by generating E11.5 epicardial cells. Real-time PCR showed that expression of PDGFR␤ transcripts was significantly reduced (supplemental Figure IV, A) . We also examined PDGFR␤ protein expression in the epicardium at E12.5 and found that PDGFR␤ was absent from the epicardium (podoplanin ϩ cells 15 ) of PDGFR␤ EKO hearts including cells surrounding the conotruncal region (supplemental Figure IV, B and C). At E13.5, we found that PDGFR␤ was absent from all epicardial cells but was still present in other smooth muscle populations and cardiac valve primordia (supplemental Figure IV, D and E). We next determined the cell populations within the heart that have had Cre activity using ROSA26 reporter mice. As shown in supplemental Figure IV, F, Cre recombination could be detected throughout the epicardium by E12.5, including the epicardium surrounding the conotruncal region and atria. Finally, to determine whether an independent epicardial Cre-deletion strain yielded similar results, we used WT1 CreGFP mice. In this mouse line, Cre is expressed very early during epicardial development and has been used to trace epicardial-derived cells. 16 Using the ROSA26 reporter to follow Cre activity, we observed that a substantial number of these cVSMCs were not epicardial derivatives (supplemental Figure  IV , G and H). Thus, it appears that there are 2 distinct cell populations for generating coronary artery VSMCs, and PDGFR␤ function is required in both populations.
Epicardium and Epicardial Derivative Formation in the PDGFR␤ ؊/؊ Hearts
Because we observed a complete absence of epicardial-derived cVSMCs, we determined whether the epicardium developed normally in our mutant hearts. To identify the proepicardium and epicardium, we used a mouse line that expresses ␤-galactosidase from the capsulin locus (capsulin LacZ/ϩ ), 17 which is expressed by proepicardial and epicardial cells. Supplemental Figure V , A and B, demonstrates that at E9.5, both wild-type and PDGFR␤ Ϫ/Ϫ embryos formed a proepicardium and have clusters of cells that have attached to the dorsal aspect of the heart. From E13.5 to E15.5, capsulin ϩ epicardial cells have spread over the surface of the heart (supplemental Figure  V , C through H). Although the PDGFR␤ Ϫ/Ϫ ; capsulin LacZϩ epicardial cell pattern appeared less uniform and exhibited small gaps between cells compared to the controls, we still concluded that epicardial cell attachment and spreading over the myocardium occurred in the absence of PDGFR␤ signaling.
After epicardial cells attach to and spread over the heart, a subset undergoes EMT and subsequently migrate into the myocardium. Using ␤-galactosidase expression from capsulin LacZ/ϩ mice to trace epicardial cell presence in the myocardium, we found that PDGFR␤ Ϫ/Ϫ hearts had reduced numbers of ␤-galactosidase ϩ cells within the myocardium at both E14.5 and E15.5 ( Figure 3A and 3B). To verify this reduction of epicardial cell derivatives in the myocardium, we used an independent marker for undifferentiated epicardial cells, Wilms tumor 1 (WT1). 18, 19 We observed a marked decrease in WT1 ϩ cells in the myocardium of PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO hearts compared to wild-type controls, although WT1-expressing cells are clearly found in the epicardium ( Figure 3C through 3H) . The reduction in epicardial-derived cells within the myocardium could be caused by either reduced proliferation, increased cell death, or decreased migration into the heart. We analyzed PDGFR␤ Ϫ/Ϫ hearts for proliferation and apoptosis and found no difference between control and PDGFR␤ Ϫ/Ϫ hearts for either of these parameters at E13.5 and E14.5 (supplemental Figure VI and supplemental Table I ). Taken together, these data suggest that the reduction of epicardial cells within the myocardium was caused by a failure of epicardial cells to exit the epicardium.
Because failure of epicardial cell migration into the myocardium could also be a result of EMT disruption, we examined the ability of PDGFR␤ Ϫ/Ϫ epicardial cells to upregulate transcription of a mesenchymal marker, vimentin. 20 At E13.5, abundant vimentin ϩ cells were observed in the myocardium of control hearts ( Figure 4A ). At E14.5, vimentin-expressing cells progressed further into the myocardium ( Figure 4C ), and at E15.5, the vimentin ϩ cells were distributed throughout the myocardium ( Figure 4E ). In contrast, fewer vimentin ϩ cells were observed within the myocardium of PDGFR␤ Ϫ/Ϫ hearts at each developmental stage, even though vimentin was expressed in PDGFR␤ Ϫ/Ϫ epicardium at each stage ( Figure 4B , 4D, and 4F). Quantification of epicardial-derived mesenchyme demonstrated a 52% reduction in vimentin ϩ cells within the heart, similar to what we observe with WT1 staining (percentage vimentin ϩ area excluding epicardium: control 11.39Ϯ2.56% [nϭ5] and PDGFR␤ Ϫ/Ϫ 5.88Ϯ1.44% [nϭ5]; PϽ0.005). In addition, there appears to be more cells in the PDGFR␤ Ϫ/Ϫ epicardium that retain vimentin expression at E14.5 and E15.5 than in wild-type epicardium. This leads to the possibility that although the cells initiate the transcription program for EMT, they lack the appropriate signals for migration. All results thus far are consistent with a role for PDGFR␤ signaling in instructing epicardial cell invasion into the myocardium.
A Role for PDGFR␤ in Epicardial Migration
The reduction in capsulin ϩ and WT1 ϩ cells within the myocardium of PDGFR␤-deficient hearts caused us to investigate epicardial cell migration in greater detail. To identify the signaling pathway responsible for epicardial cell migration, we examined hearts of mice that fail to activate specific signaling pathways downstream of the PDGFR␤ alongside PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO hearts. We first quantified the number of WT1 ϩ cells in the myocardium at E15.5. We found that both PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO hearts possessed roughly half the WT1 ϩ cells of littermate controls in both the left and right ventricles of the heart ( Figure 5A ). We next investigated WT1 ϩ cell migration in mice bearing signaling point mutants of PDGFR␤. Previous analyses have shown that cVSMC development occurs less efficiently in these animals. 21 The PDGFR␤ mutant receptors lacked PDGFR␤-induced PI3K (PDGFR␤ F2/F2 ); PI3K, RasGAP, Shp2, and PLC␥ (PDGFR␤ F5/F5 ); or Src, Grb2, PI3K, Ras- GAP, Shp2, and PLC␥ (PDGFR␤ F7/F7 ) pathways. All 3 PDGFR␤ mutant strains exhibited a 40% to 50% reduction in the number of WT1 ϩ cells within the myocardium ( Figure  5A ). Because PI3K is the only signaling pathway disrupted in all 3 mutant strains, we infer that the PI3K pathway may be the essential and predominant signaling pathway for initiating PDGFR␤-driven epicardial cell migration into the heart. This observation agrees with the known role of PI3K signaling in actin reorganization and cell migration. 22 To further evaluate epicardial cell responses to PDGF ligand stimulation, we used a wound-closure assay on epicardial monolayers. We saw that stimulation with PDGFBB and PDGFDD enhanced the rate of wound closure in wild-type cultures when compared to unstimulated cultures but had no effect on PDGFR␤ Ϫ/Ϫ culture wound closure (supplemental Table II ). The migration of PDGF-stimulated wild-type epicardial cells was similar to the migration induced by fibroblast growth factor, which also has a demonstrated role in migration of epicardial cells. 23 To directly determine whether PDGFR␤ stimulation could accelerate the number of cells entering the myocardium, we used an ex vivo system of migration. It has been demonstrated previously that the epicardial surface of hearts can be specifically labeled with the intravital fluorescent dye CCFSE to follow the epicardial cells as they undergo EMT ( Figure  5B through 5E ). 23 We cultured hearts from PDGFR␤ Ϫ/Ϫ and wild-type embryos in media containing either PDGFBB or serum. When wild-type hearts were cultured in 10% FBS, dye-labeled cells were observed in the myocardium. In contrast, when PDGFR␤ Ϫ/Ϫ hearts were cultured under the same conditions, few cells were observed entering the heart. These data suggested that in the absence of PDGFR␤ signaling, epicardial cells migrated inefficiently. When wild-type hearts were stimulated with PDGFBB, numerous labeled cells migrated into the myocardium compared to hearts stimulated by vehicle alone. These results demonstrated that PDGFR␤ is necessary and sufficient for epicardial cell migration.
To quantify the effect of PDGFR␤ signaling in epicardial cell migration and examine migration in the signaling point mutants, we performed a similar ex vivo assay using adenoviral GFP transduction of the epicardium. 24 When wild-type hearts were cultured in the presence of PDGFBB, GFP ϩ cells that migrated from the epicardium were observed in the myocardium. The response was similar to known migratory factors, transforming growth factor ␤1 and basic fibroblast factor. However, when PDGFR␤ (F2/F2, F5/F5, F7/F7) mutant hearts were cultured with PDGFBB, a significant reduction of GFP ϩ cells within the myocardium was observed. Additionally, wild-type hearts treated with a PI3K inhibitor (LY294002) and stimulated with PDGFBB showed a reduction in migration similar to PDGFR␤ F2/F2 signaling mutants ( Figure 5F ). Consistent with our previous data, these data suggest the PI3K pathway is essential for PDGFR␤driven epicardial cell migration and is the dominant signaling pathway involved in this response.
Cellular Morphology and Cytoskeletal Organization in PDGFR␤ ؊/؊ Epicardial Cells
Because proper organization of the cytoskeleton is essential for cell migration, we examined actin localization in epicardial cells. Using phalloidin staining, we imaged actin organization of hearts in whole mount and in sections of E14.5 PDGFR␤ ϩ/ϩ and PDGFR␤ Ϫ/Ϫ hearts ( Figure 6A through  6D) . In wild-type hearts, actin was consistently localized to the basal surface of the epicardial cells ( Figure 6A and 6C) . However, PDGFR␤ Ϫ/Ϫ and PDGFR␤ EKO/Ϫ hearts showed an increase in cells that exhibited a subcortical actin distribution ( Figure 6B and 6D through 6E) . Consistent with a role for PI3K in actin localization, PDGFR␤ F2/F2 hearts also demonstrated an increase in cortical actin localization ( Figure 6E) .
We examined the ultrastructure of epicardial cells at E14.5 ( Figure 6F through 6I) . Transmission electron microscopy (TEM) revealed that epicardial cells in PDGFR␤ Ϫ/Ϫ hearts lacked the epithelial morphology exhibited by wild-type epicardial cells. Occasionally, a few rounded cells were observed in wild-type hearts, but these were rare in occurrence compared to the number of those observed in PDGFR␤ Ϫ/Ϫ . These results further support a role for PDGFR␤ in promoting the cellular processes involved in actin reorganization and migration of epicardial cells.
PI3K Signaling Is Required for PDGFR␤-Dependent Cortactin Localization
We next examined the phosphorylation status of proteins downstream of the PI3K pathway (AKT, p70S6K, GSK3␤) and involved in actin polymerization (cortactin) in LY294002-treated and PDGFR␤ F2/F2 epicardial cultures. PDGFDD stimulation of wild-type epicardial cells induced phosphorylation of AKT, GSK3␤, p70S6K, cortactin, and extracellular signal-regulated kinase 1/2 ( Figure 7A ), but when PI3K signaling was disrupted, phosphorylation of all of these proteins was significantly reduced or absent, with the exception of extracellular signal-regulated kinase 1/2. Residual AKT and p70S6K activation was observed in PDGFR␤ F2/F2 epicardial cells. This was likely attributable to the fact that epicardial cells express both PDGFR␣ and PDGFR␤ and PDGFDD weakly induces PDGFR␣/␤ heterodimers. 25 Because activation of many PI3K downstream components is associated with actin polymerization, we next evaluated the ability of epicardial cells to form lamellipodia and localize proteins to these cellular areas ( Figure 7B and supplemental Figure VII ). Stimulation with PDGFDD increased cortactin localization to lamellipodia in wild-type cells. However, PDGFR␤ stimulation was unable to direct cortactin to lamellipodia in PDGFR␤ EKO/Ϫ or LY294002-treated cells. These data suggest PI3K is required downstream of PDGF signaling for activating proteins involved in actin reorganization and localizing cortactin to the leading edge of a migrating cell.
Discussion
The epicardium retains stem cell-like properties and when given the appropriate cues, it can differentiate into multiple cardiac cell types. 26 -28 In a zebrafish cardiac injury model, the epicardium is an essential component of the regeneration process. 29 In addition to being a source of cardiac 16, 26 and vascular cells, 2,3 the epicardium also secretes growth factors essential for myocardial development. 30, 31 Therefore, a better understanding of the epicardium during development may help define the signals essential for reactivation of these differentiation processes to improve outcomes of human heart disease.
We show that PDGFR␤ provides essential cues for efficient epicardial migration, cVSMC formation, and coronary vessel maturation. Previous expression studies have demonstrated ligands and receptors within the epicardium foreshadowing a requirement for PDGF signal transduction. 12, 32 Explant studies in rat and chick proepicardial and epicardial cells have demonstrated that stimulation with PDGF ligands leads to filamentous actin formation and expression of smooth muscle cell markers. 33, 34 We now provide in vivo illustration of the role for PDGFR␤ in epicardial function and show that disruption of this signaling impacts more than just VSMC proliferation. The heart is the first tissue to demonstrate an absolute requirement for PDGFR␤ signaling to promote VSMC differentiation. In most other tissues, VSMC differentiation occurs but expansion is disrupted in the absence of PDGFR␤. 4 It is an established fact that VSMCs are a heterogeneous population and that they come from a vast range of embryonic origins. In the chick, lineage-tracing analysis has demonstrated that the majority of cVSMCs are derived from the proepicardium. 3, 35, 36 Consistent with recent lineage tracing studies, 16, 26 we have shown that in the mouse, a majority of VSMCs also arises from the epicardium. However, 1 question concerning the heterogeneity of cVSMCs is the origin of the residual cells that are present around the coronary arteries in PDGFR␤ epicardial mutant hearts. From the present experiments, it is difficult to determine whether these cVSMCs arise ectopically because of the absence of epicardially derived VSMCs, or whether they are a normal subpopulation of cells contributing to the coronary arteries. Both neural crest-derived cells and cells from the secondary heart field can contribute to VSMCs in the outflow tract and the coronary arteries. [37] [38] [39] The possibility that cVSMCs are het- erogeneous in origin is an important consideration because the 2 cell populations are likely to express different genes and respond differently under pathological conditions or in response to pharmacological intervention.
Based on our analysis of the formation of the coronary vessels in PDGFR␤ mutant hearts, we propose that PDGFR␤ signaling can indirectly help shape the mature coronary vasculature. The observation that the coronary artery defects in PDGFR␤ EKO but not PDGFR␤ Ϫ/Ϫ hearts improve over time suggests that cVSMCs may be involved in the coronary vessel remodeling process. We have shown that cVSMC formation was completely disrupted, whereas epicardial cell migration was reduced but not abrogated in PDGFR␤ Ϫ/Ϫ hearts. The most likely explanation for this observation is that presence of PDGFR␣ can compensate for loss of PDGFR␤ in the epicardium but not cVSMCs. These 2 receptors signal through very similar pathways and can bind some but not all of the same ligands. 40 We have recently shown that PDGF receptor function in neural crest cells is also partially redundant, therefore ligand availability may be a key factor in determining the contribution of each receptor. The exquisite expression of the PDGFDD ligand in the epicardium, 32 which predominantly activates PDGFR␤, 41 could favor signaling through the PDGFR␤. Therefore, it is possible that PDGFDD may provide an autocrine signal that induces cytoskeletal rearrangements necessary for EMT. Recently, PDGFDD overexpression has been demonstrated to induce an EMT-like transformation in prostate cancer cells. 42 Our present data cannot determine the temporal requirement for PDGFR␤ signaling. The migration defect we observe may predominantly affect only the cells destined to become cVSMCs. In this scenario, cVSMC progenitors might not reach their final destination to receive the differentiation cues from myocardium or endothelium. In support of this possibility, clonal analysis of VSMCs in the chick has shown that specification of VSMCs occurs before the formation of the epicardium and that some VSMC markers are expressed in the proepicardium. 3 Because the requirement for PDGFR␤ signaling in many tissues is to promote VSMC proliferation, 6, 7 another way to explain our results is that PDGFR␤ may be required at 2 stages: within the epicardium for migration and within the epicardial-derived mesenchyme to promote VSMC differentiation or expansion.
A role for PDGFR␤ in directing cytoskeletal rearrangements via PI3K has been established in multiple cell types (reviewed by Heldin et al 43 ) . Here, we have demonstrated that PDGF stimulation of PI3K is also required for cortactin localization to lamellipodia. The failure of cortactin localization is likely attributable to the loss of PI3K-induced Rac activation. 44 The epicardial cells are incapable of controlling directed actin filament growth, and directed migration into the myocardium is inefficient.
In conclusion, we have demonstrated a novel role for the PDGFR␤ in epicardial development in vivo and identified PI3K signaling as 1 of the pathways associated with this process. In the absence of this signaling, the epicardium fails to adopt a motile phenotype, leading to a reduction in cVSMCs and abnormal coronary vessels. Overall, these findings suggest that PDGF signaling is acting to promote epicardial migration and that modulation of PDGF receptor signaling should be considered when exploring options for therapeutic applications of epicardial-derived cells. 
Sources of Funding
Disclosures
None.
